摘要
目的:了解2012-2016年东方肝胆外科医院住院患者肝胆疾病辅助用药应用情况及发展趋势,为临床合理应用提供参考。方法:采用用药频度分析方法,对我院2012-2016年保肝药总销售金额、用药频度(DDDs)、限定日费用(DDC)等进行回顾性统计分析。结果:销售金额和用药频度均位于前10名的肝胆疾病辅助用药为异甘草酸镁注射液、注射用还原型谷胱甘肽、注射用丁二磺酸腺苷蛋氨酸、谷胱甘肽片、多烯磷脂酰胆碱注射液、熊去氧胆酸胶囊、双环醇片、复方甘草酸苷片。其中异甘草酸镁注射液、门冬氨酸鸟氨酸注射液、注射用丁二磺酸腺苷蛋氨酸、苦黄注射液、促肝细胞生长素的限定日费用值居高不下。结论:我院肝胆疾病辅助用药应用相对合理,符合安全、有效、经济的用药原则。
Objective： To evaluate the application and trend of liver protective drugs for hepatobiliary diseases in Eastern Hepatobiliary Surgery Hospital from 2012 to 2016 and to provide references for rational drug use. Methods： The total sale amount, defined daily dose system （DDDs） and defined daily cost （DDC） were retrospectively analyzed according to the method of frequency analysis. Results： The top 10 liver protective t drugs in sale amount and DDDs consisted of magnesium isoglycyrrhizinate injection, reduced glutathione for injection, ademetionine 1, 4-butanedisulfonate for injection, glutathione tablets, polyene phosphatidylcholine injection, ursodeoxycholic acid capsules, bicycloI tablets and compound glycyrrhizin tablets. The DDC of magnesium isoglycyrrhizinate injection, ornithine aspartate injection, ademetionine 1, 4-butanedisulfonate for injection, Kuhuang injection and hepatocyte growth-promoting factors were high. Conclusion： The application of liver protective drugs in our hospital was relatively reasonable, in line with the medication principle of safety, effectiveness and economy.
出处
《中国药事》
CAS
2018年第2期267-274,共8页
Chinese Pharmaceutical Affairs
